Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study
Aims To explore the cardiac safety of adjuvant Non-Pegylated Liposomal Doxorubicin (NPL-DOX) plus Cyclophosphamide (CTX) followed by weekly Paclitaxel, in elderly women (≥ 65 years) with high-risk breast cancer. Previously, we described no symptomatic cardiac events within the first 12 months from starting treatment. We now reported the updated results after a median follow-up 76 months. Methods The cardiac activity was evaluated with left ventricular ejection fraction (LVEF) echocardiograms assessments, before starting chemotherapy and every 6 months, until 30 months from baseline, then yearly for at least 5 years. Results Forty-seven women were recruited by two Units of Medical Oncology (Ethics Committee authorization CESM-AOUP, 3203/2011; EudraCT identification number: 2010-024067-41, for Pisa and Pontedera Hospitals). An episode of grade 3 CHF (NCI-CTCAE, version 3.0) occurred after 18 months the beginning of chemotherapy. The echocardiograms assessments were performed comparing the LVEF values of each patient evaluated at fixed period of time, compared to baseline. We observed a slight changed in terms of mean values at 48, 60, 72 and 84 months. At these time points, a statistically significant reduction of − 3.2%, − 4.6%, − 6.4% and − 7.1%, respectively, was observed. However, LVEF remained above 50% without translation in any relevant clinical signs. No other cardiac significant episodes were reported. To this analysis, in 13 patients (28%) occurred disease relapse and, of them, 11 (23%) died due to metastatic disease. Eight patients died of cancer-unrelated causes. Conclusions The combination including NPL-DOX in elderly patients revealed low rate of cardiac toxic effects. Comparative trials are encouraged..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Clinical and experimental medicine - 23(2023), 8 vom: 27. Aug., Seite 5113-5120 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Coltelli, Luigi [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Adjuvant chemotherapy |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s10238-023-01144-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054109426 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054109426 | ||
| 003 | DE-627 | ||
| 005 | 20231217064612.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231217s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10238-023-01144-8 |2 doi | |
| 035 | |a (DE-627)SPR054109426 | ||
| 035 | |a (SPR)s10238-023-01144-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coltelli, Luigi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Aims To explore the cardiac safety of adjuvant Non-Pegylated Liposomal Doxorubicin (NPL-DOX) plus Cyclophosphamide (CTX) followed by weekly Paclitaxel, in elderly women (≥ 65 years) with high-risk breast cancer. Previously, we described no symptomatic cardiac events within the first 12 months from starting treatment. We now reported the updated results after a median follow-up 76 months. Methods The cardiac activity was evaluated with left ventricular ejection fraction (LVEF) echocardiograms assessments, before starting chemotherapy and every 6 months, until 30 months from baseline, then yearly for at least 5 years. Results Forty-seven women were recruited by two Units of Medical Oncology (Ethics Committee authorization CESM-AOUP, 3203/2011; EudraCT identification number: 2010-024067-41, for Pisa and Pontedera Hospitals). An episode of grade 3 CHF (NCI-CTCAE, version 3.0) occurred after 18 months the beginning of chemotherapy. The echocardiograms assessments were performed comparing the LVEF values of each patient evaluated at fixed period of time, compared to baseline. We observed a slight changed in terms of mean values at 48, 60, 72 and 84 months. At these time points, a statistically significant reduction of − 3.2%, − 4.6%, − 6.4% and − 7.1%, respectively, was observed. However, LVEF remained above 50% without translation in any relevant clinical signs. No other cardiac significant episodes were reported. To this analysis, in 13 patients (28%) occurred disease relapse and, of them, 11 (23%) died due to metastatic disease. Eight patients died of cancer-unrelated causes. Conclusions The combination including NPL-DOX in elderly patients revealed low rate of cardiac toxic effects. Comparative trials are encouraged. | ||
| 650 | 4 | |a Early breast cancer patients |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a High risk |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Adjuvant chemotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cardiac safety |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Non-pegylated liposomal doxorubicin |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Finale, Chiara |4 aut | |
| 700 | 1 | |a Musettini, Gianna |4 aut | |
| 700 | 1 | |a Fontana, Andrea |4 aut | |
| 700 | 1 | |a Barletta, Maria Teresa |4 aut | |
| 700 | 1 | |a Lucarini, Alessandra Renata |4 aut | |
| 700 | 1 | |a Fabiani, Iacopo |4 aut | |
| 700 | 1 | |a Scalese, Marco |4 aut | |
| 700 | 1 | |a Bocci, Guido |4 aut | |
| 700 | 1 | |a Masini, Luna Chiara |4 aut | |
| 700 | 1 | |a Soria, Giulia |4 aut | |
| 700 | 1 | |a Cupini, Samanta |4 aut | |
| 700 | 1 | |a Arrighi, Giada |4 aut | |
| 700 | 1 | |a Barbara, Cecilia |4 aut | |
| 700 | 1 | |a De Maio, Ermelinda |4 aut | |
| 700 | 1 | |a Salvadori, Barbara |4 aut | |
| 700 | 1 | |a Marini, Andrea |4 aut | |
| 700 | 1 | |a Pellino, Antonio |4 aut | |
| 700 | 1 | |a Stasi, Irene |4 aut | |
| 700 | 1 | |a Emdin, Michele |4 aut | |
| 700 | 1 | |a Giaconi, Stefano |4 aut | |
| 700 | 1 | |a Marcucci, Lorenzo |4 aut | |
| 700 | 1 | |a Allegrini, Giacomo |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental medicine |d Milano : Springer, 2001 |g 23(2023), 8 vom: 27. Aug., Seite 5113-5120 |w (DE-627)SPR009227598 |w (DE-600)2054398-0 |x 1591-9528 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:8 |g day:27 |g month:08 |g pages:5113-5120 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10238-023-01144-8 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 8 |b 27 |c 08 |h 5113-5120 | ||